GE HealthCare Technologies Inc. - Common Stock (GEHC)
76.10
+0.00 (0.00%)
NASDAQ · Last Trade: Oct 22nd, 6:00 AM EDT
Detailed Quote
Previous Close
76.10
Open
-
Bid
76.10
Ask
76.96
Day's Range
N/A - N/A
52 Week Range
57.65 - 94.80
Volume
1
Market Cap
34.55B
PE Ratio (TTM)
15.59
EPS (TTM)
4.9
Dividend & Yield
0.1400 (0.18%)
1 Month Average Volume
2,924,778
Chart
About GE HealthCare Technologies Inc. - Common Stock (GEHC)
GE HealthCare Technologies Inc. is a leading global medical technology and digital solutions innovator focused on improving patient outcomes through advanced healthcare solutions. The company develops and manufactures a wide range of diagnostic imaging systems, monitoring devices, and healthcare IT services that empower healthcare providers to deliver accurate and efficient patient care. Through its commitment to innovation, GE HealthCare supports clinicians and patients by providing tools that enhance diagnostic capabilities, streamline workflows, and facilitate data-driven decision-making in an increasingly complex healthcare environment. Read More
NetworkNewsWire Editorial Coverage : Artificial intelligence (“AI”) is making inroads into every corner of medical technology, perhaps none more urgently than imaging. In breast cancer detection, where early diagnosis can mean the difference between life and death, AI-enhanced modalities present a chance to leap beyond the limits of mammography, tomosynthesis, and MRI. Globally, breast cancer remains one of the most common cancers in women. According to the World Health Organization (“WHO”), more than 2.3 million women were diagnosed with breast cancer in 2022, and approximately 670,000 women died from the disease globally. In the United States, the American Cancer Society (“ACS”) projects that 316,950 new invasive breast cancer cases will be diagnosed among women this year. The urgent, life-saving need for earlier and more accurate detection creates a powerful opportunity for innovation in diagnostic imaging. Amid this global challenge, companies advancing breast cancer diagnostics are entering a high-impact field. Among them, Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) ( profile ) stands out with its next-generation IzoView Breast CT Imaging System, a dedicated 3D imaging platform designed to improve detection accuracy, particularly for women with dense breast tissue. IzoView joins an elite group of companies, including Hologic Inc. (NASDAQ: HOLX), GE HealthCare Technologies Inc. (NASDAQ: GEHC), Nano-X Imaging Ltd. (NASDAQ: NNOX) and Oracle Corp. (NYSE: ORCL), that are focused on playing a….
GE HealthCare (Nasdaq: GEHC) today announced collaborations with two leading U.S. health systems—The Queen’s Health Systems in Honolulu, HI and Duke Health in Durham, NC—to help advance the development of GE HealthCare’s new AI-driven hospital operations software. Both health systems plan to contribute their frontline expertise to inform GE HealthCare’s forthcoming cloud-first Software as a Service solution that will be part of GE HealthCare’s CareIntellect family of applications. User feedback is central to GE HealthCare’s customer-driven approach to developing solutions that tackle health systems’ biggest needs and provide better, faster care to more patients. The new solution will use AI and predictive analytics to recommend actions. These features are designed to give hospital leaders the actionable insights and suggestions they need to adjust in real-time to deliver high-quality, efficient care.
GE HealthCare (Nasdaq: GEHC) today announced the launch of CareIntellect™ for Perinatal2, a cloud-first Software-as-a-Service (SaaS) application designed to deliver clear, actionable insights that help clinicians improve maternal and fetal care.3 CareIntellect for Perinatal supports clinicians by integrating information from disparate clinical sources in a single place, making it fast and easy for clinicians to monitor status, annotate clinical events, search historical data, and remotely monitor patients—with the aim of providing timely patient insights. This is the second application within GE HealthCare’s CareIntellect family of clinical and operational applications, built to help healthcare systems quickly and easily deploy and scale new applications.
GE HealthCare (Nasdaq: GEHC) today announced the presentation of findings from the largest real-world evidence study to-date on End-tidal Control anesthesia delivery* software conducted at the University of Michigan. The results demonstrated the environmental and clinical benefits of End-tidal Control software and were presented at ANESTHESIOLOGY® 2025 taking place from October 10-14, in San Antonio, Texas.
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
GE HealthCare (Nasdaq: GEHC) today announced the unveiling of Carestation™ 850, its next-generation, FDA 510(k) pendingi anesthesia delivery system that is designed to help care teams adapt to evolving clinical and operational needs. Marking the latest evolution of GE HealthCare’s Carestation portfolio, Carestation 850 has the potential to advance anesthesia care through tools, customizable applications, and a sleek, space conscious footprint. The FDA 510(k) submission for Carestation 850 follows the recent CE mark in Europe and Australian Therapeutic Goods approval in Australia and New Zealand.
Clairity Inc. is set to transform the landscape of early breast cancer detection with its groundbreaking AI-powered risk prediction technology, Clairity Breast. Having secured De Novo authorization from the U.S. Food and Drug Administration (FDA) in late May 2025, this innovative platform is the first artificial intelligence tool authorized
A groundbreaking development from the University of Waterloo is poised to revolutionize the early assessment and treatment of spinal cord injuries (SCI) through AI-driven analysis of routine blood tests. This innovative approach, spearheaded by Dr. Abel Torres Espín's team, leverages machine learning to uncover hidden patterns within common blood measurements, providing clinicians with unprecedented insights [...]
Hong Kong, October 3, 2025 – A significant leap forward in medical diagnostics is emerging from the vibrant tech hub of Hong Kong, where local startup Caretia is pioneering an AI-powered platform designed to dramatically improve early detection of lung cancer. Leveraging sophisticated deep learning and computer vision, Caretia's innovative system promises to enhance the [...]
Merit Medical Systems (NASDAQ: MMSI) has announced a significant milestone for its SCOUT Radar Localization technology, which has now been utilized in over 750,000 patient procedures worldwide. This achievement, coinciding with Breast Cancer Awareness Month, underscores the widespread adoption and critical impact of the wire-free, non-radioactive localization device in
Hastings, MN – October 3, 2025 – Allina Health has officially launched advanced Cardiac MRI services at its Hastings Regina Hospital, marking a significant leap forward in cardiovascular diagnostics and patient care for the southeast Twin Cities metro area. This strategic enhancement brings world-class, non-invasive heart imaging capabilities closer to home, promising
On October 2, 2025, the Healthcare sector emerged as a beacon of stability and growth within the S&P 500, delivering a robust positive performance that significantly contributed to the broader market's resilience. Despite prevailing anxieties, including a looming U.S. government shutdown and a disappointing jobs report, healthcare equities
CHICAGO, IL – October 2, 2025 – The Radiological Society of North America (RSNA) today announced the official launch of RSNA Ventures, a groundbreaking mission-aligned subsidiary poised to revolutionize the landscape of radiology and imaging technology. This strategic initiative aims to actively identify, accelerate, and support groundbreaking ideas that promise to enhance
As of October 1, 2025, Artificial Intelligence (AI) has transcended its nascent stages, becoming an indispensable force in high-value professional tasks across medicine, law, and consulting. This transformative shift is redefining traditional workflows, demanding a radical re-evaluation of skill sets, and igniting critical discussions around ethics, regulation, and the very
GE HealthCare (Nasdaq: GEHC) will announce its third quarter 2025 financial results before the market opens on Wednesday, October 29, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website.
A highly volatile stock can deliver big gains - or just as easily wipe out a portfolio if things go south.
While some investors embrace risk, mistakes can be costly for those who aren’t prepared.
As the medical community converges for the 67th Annual Meeting of the American Society for Radiation Oncology (ASTRO 2025) in San Francisco, a groundbreaking showcase by Fuse Oncology is poised to redefine the landscape of cancer care. Commencing on September 27 or 28, 2025, Fuse Oncology will present its suite
The U.S. Commerce Department, under the Trump administration, has launched a national security review of medical imports—including PPE, consumables, and medical devices—to assess reliance on foreign suppliers for critical health products.
Shares of healthcare technology company GE HealthCare Technologies (NASDAQ:GEHC)
fell 4.3% in the afternoon session after the U.S. Commerce Department initiated a national security investigation into medical equipment and devices, raising concerns about potential tariffs.
Wondering which stocks are making significant price gaps? Explore the S&P500 index on Thursday to find the gap up and gap down stocks in today's session.
GE HealthCare (Nasdaq: GEHC) today announced updates to Intelligent Radiation Therapy (iRT), a new version of the company’s software solution for radiation therapy workflow management, designed to reduce the time it takes for patients to go from diagnosis to treatment. The iRT solution is AI-supported by GE HealthCare and third-party applications, and the latest features bring enhanced connectivity to the systems radiation oncology departments use most and use insights to improve departmental efficiency. The company also unveiled a new capability for theranostics that manages these complex workflows throughout the patient treatment journey, extending its expertise in radiation therapy workflows to this evolving field. The latest updates will be showcased at the American Society for Radiation Oncology (ASTRO) 2025 Annual Meeting in San Francisco for the first time.
